Department of Neurosurgery, Antwerp University Hospital, Antwerp, Belgium.
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Eur Spine J. 2024 Sep;33(9):3559-3566. doi: 10.1007/s00586-024-08448-7. Epub 2024 Aug 21.
Lumbar spinal fusion surgeries are increasingly being performed in spinal degenerative disease, often accompanied by perioperative opioid prescriptions. The aim of this study is to analyze prolonged postoperative opioid use following a standardized opioid prescription after single-level lumbar spinal fusion surgery in a Belgian population.
This prospective, multicentric observational study included patients undergoing single-level lumbar fusion surgery for degenerative disease. A standardized postoperative opioid protocol (Targinact 2 × 10 mg/5 mg, Paracetamol 4 × 1 g and Ibuprofen 3 × 600 mg) was applied uniformly. Prolonged opioid use was defined as continued opioid use six months after surgery. Patient data were collected using the Back-App.
Among 198 participants, 32.8% continued opioid use six months post-surgery, with 8% utilizing strong opioids. Prolonged opioid use correlated with lower pre-operative back pain. Patients with prolonged opioid use and strong opioid use at six months show less improvement in disability compared to patients without prolonged opioid use. Moreover, patients with prolonged strong opioid use tend to have lesser improvement of the low back pain. The odds for prolonged opioid use decrease with the increase of the improvement in ODI.
1 in 3 patients undergoing single-level lumbar spinal fusion surgery is at risk for prolonged opioid use. The study underscores the importance of tailored pain management strategies, particularly given the rising prevalence of spinal fusion surgeries. The association between pre-operative low back pain, post-operative improvement in functionality (ODI), and prolonged opioid use emphasizes the need for judicious opioid prescribing practices and highlights the role of functional outcomes in treatment goals.
腰椎融合术在脊柱退行性疾病中的应用日益增多,常伴有围手术期阿片类药物处方。本研究旨在分析在比利时人群中单节段腰椎融合术后,按照标准阿片类药物处方,术后长期使用阿片类药物的情况。
这是一项前瞻性、多中心观察性研究,纳入因退行性疾病接受单节段腰椎融合术的患者。统一应用标准化术后阿片类药物方案(Targinact 2×10mg/5mg、对乙酰氨基酚 4×1g 和布洛芬 3×600mg)。将术后持续使用阿片类药物 6 个月定义为长期使用阿片类药物。使用 Back-App 收集患者数据。
在 198 名参与者中,32.8%的患者在术后 6 个月继续使用阿片类药物,其中 8%使用强阿片类药物。长期使用阿片类药物与术前腰痛程度较低相关。与无长期阿片类药物使用的患者相比,长期使用阿片类药物和 6 个月时使用强阿片类药物的患者,其残疾程度改善较少。长期使用强阿片类药物的患者腰痛改善程度也较低。随着 ODI 改善程度的增加,长期使用阿片类药物的可能性降低。
接受单节段腰椎融合术的患者中,有 1/3 存在长期使用阿片类药物的风险。该研究强调了制定个体化疼痛管理策略的重要性,特别是考虑到脊柱融合手术的患病率不断上升。术前腰痛、术后功能(ODI)改善与长期阿片类药物使用之间的关联,强调了合理开具阿片类药物处方的必要性,并突出了功能结局在治疗目标中的作用。